|
|
|
|
|
|
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
|
|
|
|
|
|
|
|
|
|
|
FORM
12b-25
|
SEC
FILE NUMBER
|
|
|
0001416172
|
|
|
|
|
|
|
|
CUSIP
NUMBER
|
|
|
NOTIFICATION OF
LATE FILING
|
65342G104
|
|
(Check
one):
|
☒ Form
10-K ☐ Form 20-F ☐ Form
11-K ☐ Form 10-Q ☐ Form
10-D
☐ Form N-SAR ☐ Form N-CSR
|
|
|
|
|
|
For
Period Ended:
December 31, 2018
☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
☐ Transition Report on Form N-SAR
For the Transition Period Ended: ____________________
|
|
Read Instruction (on
back page) Before Preparing Form. Please Print or Type.
Nothing in this form
shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
|
NEXEON MEDSYSTEMS INC
|
|
Full Name of Registrant
|
|
|
|
|
|
Former Name if Applicable
|
|
|
|
1910 Pacific Avenue, Suite 20000
|
|
Address of Principal Executive Office
(Street and Number)
|
|
|
|
Dallas,
Texas 75201
|
|
City, State and Zip Code
|
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
|
|
☒
|
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
(c)
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K,
20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
Nexeon MedSystems Inc. (the
“Company”) is unable to file its annual report on Form 10-K for the year ended December 31, 2018 within the prescribed
period. The compilation, dissemination and review of the financial information required to be presented in the Form 10-K has imposed
time constraints on the Company’s management that have rendered timely filing of the Form 10-K impractical without undue
hardship and expense to the Company. At this time, the Company expects to file the Form 10-K no later than the fifteenth calendar
day following the prescribed due date, as permitted by Rule 12b-25.
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
|
|
|
|
|
|
|
|
(1)
|
Name and telephone number of person
to contact in regard to this notification
|
|
|
|
|
Christopher
Miller
|
|
(844)
|
|
919-9990
|
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
(2)
|
Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940
during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?
If answer is no, identify report(s).
|
|
|
|
|
Yes ☒ NO ☐
|
|
|
|
|
|
|
|
|
(3)
|
Is it anticipated that any significant
change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements
to be included in the subject report or portion thereof?
|
|
|
|
|
Yes ☒ NO ☐
|
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively,
and, if appropriate, state the reasons why a reasonable estimate of the results cannot
be made.
|
Anticipated
changes in results of operations for the year ended December 31, 2018 from the prior year ended December 31, 2017 are due to the
acquisition of Medi-Line, S.A (“Medi-Line”) and its holding company INGEST, SPRL (“INGEST”) on August
30, 2017.
Reporting
in the Company’s financial statements for the year ended December 31, 2018 includes twelve months activity, respectively,
for INGEST and Medi-Line compared to the year ended December 31, 2017 which includes four months of activity for INGEST and Medi-Line.
NEXEON MEDSYSTEMS INC
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date:
|
March
29, 2019
|
|
By:
|
/s/ Christopher Miller
|
|
|
|
|
|
Chief Financial Officer
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized
representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement
is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s
authority to sign on behalf of the registrant shall be filed with the form.
|
ATTENTION
Intentional misstatements
or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
|
GENERAL INSTRUCTIONS
|
|
1.
|
This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General
Rules and Regulations under the Securities Exchange Act of 1934.
|
|
|
2.
|
One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule
0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter
of public record in the Commission files.
|
|
|
3.
|
A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of the registrant is registered.
|
|
|
4.
|
Amendments to the notifications must also be filed on Form 12b-25 but need
not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
|
|
|
5.
|
Electronic Filers:
This form shall not be used by electronic filers
unable to timely file a report solely due to electronic difficulties. Filers unable to submit reports within the time period prescribed
due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202
of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this chapter).
|
|
|
6.
|
Interactive data submissions
.
This form shall not be used by
electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic
filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or
202 of Regulation S-T (§232.201 and §232.202 of this chapter).
|
Nexeon Medsystems (CE) (USOTC:NXNN)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Nexeon Medsystems (CE) (USOTC:NXNN)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
